Evidence map›Paper›PMID 41705139›Full record

ArticleTherapeutic advances in medical oncology2026

Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4.

Karolina Mangani, Evangelia Pantazaka, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis, Athina Markou, Galatea Kallergi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karolina ManganiLaboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, Patras, Greece.ORCID https://orcid.org/0009-0005-0263-1388
Evangelia PantazakaLaboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, Patras, Greece.ORCID https://orcid.org/0000-0001-6737-8428
Evi LianidouAnalysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0002-7796-5914
Vassilis GeorgouliasHellenic Oncology Research Group, Athens, Greece.ORCID https://orcid.org/0000-0003-2218-2522
Athanasios KotsakisDepartment of Medical Oncology, University General Hospital of Larissa, Larissa, Greece.ORCID https://orcid.org/0000-0002-5530-6774
Athina MarkouAnalysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.ORCID https://orcid.org/0000-0001-7760-9701
Galatea KallergiLaboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, Patras 26504, Greece.ORCID https://orcid.org/0000-0001-9825-3871

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Monocarboxylate transporters (MCTs) facilitate lactate transfer and support cancer cell survival and metastasis. MCT1 and MCT4 expression has been associated with poor prognosis and resistance to therapy with tyrosine kinase inhibitors. Objectives: This pilot study examined the relevance of MCT1 and MCT4 expression in circulating tumour cells (CTCs) isolated from non-small cell lung cancer (NSCLC) patients during osimertinib treatment through single-cell analysis. Design: Fifty-three NSCLC patients were enrolled at three different time points: baseline ( Methods: CTCs were isolated with the ISET platform. MCT1/MCT4 expression was assessed using immunofluorescence triple staining experiments and confocal laser scanning microscopy. Results: CTCs were detected in 75% (40/53), 40% (8/20) and 29% (6/21) of patients at baseline, post-first cycle and PD, respectively. Among cytokeratin (CK)-positive patients, MCT1 was overexpressed at all time points in a significant percentage: 67% (18/27) at baseline, 57% (4/7) at post-first cycle and 50% (2/4) at PD. Similarly, MCT4 was overexpressed in 55% (16/29), 50% (2/4) and 60% (3/5) of cases, respectively. Statistical analysis revealed that the (CK+MCT1-CD45-) phenotype was associated with worse progression-free survival [PFS; log rank, Conclusion: MCT1 and MCT4 are overexpressed in CTCs from NSCLC patients, supporting their potential as prognostic biomarkers and therapeutic targets.

Indexed as

biomarkercirculating tumour cells (CTCs)monocarboxylate transporter 1 (MCT1)monocarboxylate transporter 4 (MCT4)non-small cell lung cancer (NSCLC)

Identifiers

PMID41705139
PMCPMC12907484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.